Massive haemoptysis
Massive haemoptysis is a medical emergency and requires immediate treatment. Massive haemoptysis is defined as the expectoration of blood from a source below the glottis exceeding 600 mL of blood over a 24-hour period or 150 mL of blood (which may flood the lung dead space) over a 1-hour period.
Alternatively, massive haemoptysis can be diagnosed by clinical features of: airway compromise (obstruction, aspiration, hypoxaemia, need for intubation); haemodynamic instability or requirement for blood transfusion.[3]Sakr L, Dutau H. Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management. Respiration. 2010 Jan 8;80(1):38-58.
https://www.karger.com/Article/FullText/274492
http://www.ncbi.nlm.nih.gov/pubmed/20090288?tool=bestpractice.com
Experts recommend a stepwise approach to treat massive haemoptysis:
1. Initial stabilisation
Initial priorities are assessment of the need for intubation or mechanical ventilation, and protection of the non-bleeding lung. Attending to ABC (Airway, Breathing, and Circulation) is paramount. Coagulopathy, thrombocytopenia, and platelet dysfunction should be identified and reversed immediately, and blood products should be readily available.
2. Protection of the non-bleeding lung
If haemoptysis is active and unilateral, there is risk of blood spillage into the non-bleeding lung, and rapid action should be taken to protect the non-bleeding lung. The patient may be placed in a lateral decubitus position with the bleeding lung downward in a dependent position.[5]Davidson K, Shojaee S. Managing massive hemoptysis. Chest. 2020 Jan;157(1):77-88.
http://www.ncbi.nlm.nih.gov/pubmed/31374211?tool=bestpractice.com
Alternatively, the non-bleeding lung may be selectively intubated with the largest endotracheal tube available. A double-lumen endotracheal tube has a very limited role in managing massive haemoptysis due to the complexity of its proper placement, the need for significant operator experience, and the small lumen sizes, which do not allow room for therapeutic bronchoscopy.[5]Davidson K, Shojaee S. Managing massive hemoptysis. Chest. 2020 Jan;157(1):77-88.
http://www.ncbi.nlm.nih.gov/pubmed/31374211?tool=bestpractice.com
3. Airway intervention and control of bleeding
Once the patient has been stabilised and the non-bleeding lung has been protected, early bronchoscopy should be performed. Airway control can be attained by flexible bronchoscopy through a large-bore endotracheal tube or through the barrel of a rigid bronchoscope. Rigid bronchoscopy is a safe, effective way of securing the airway with therapeutic control of bleeding.[7]Comforti J. Management of massive hemoptysis. In: Simoff MJ, Sterman DH, Ernst A, eds. Thoracic endoscopy: advances in interventional pulmonology. Malden, MA: Blackwell Publishing; 2006:23:330-43.[28]Wahidi MM, Herth FJ, Ernst A. State of the art: interventional pulmonology. Chest. 2007 Jan;131(1):261-74.
http://www.ncbi.nlm.nih.gov/pubmed/17218585?tool=bestpractice.com
[29]Folch E, Mehta AC. Airway interventions in the tracheobronchial tree. Semin Respir Crit Care Med. 2008 Aug;29(4):441-52.
http://www.ncbi.nlm.nih.gov/pubmed/18651361?tool=bestpractice.com
[30]Jeon K, Kim H, Yu CM, et al. Rigid bronchoscopic intervention in patients with respiratory failure caused by malignant central airway obstruction. J Thorac Oncol. 2006 May;1(4):319-23.
http://www.ncbi.nlm.nih.gov/pubmed/17409877?tool=bestpractice.com
An endobronchial blocker or Fogarty balloon may be placed into the bleeding bronchus for tamponade of the bleeding site.
Bronchial arteriography with embolisation of the source of bleeding can be used as a diagnostic and therapeutic intervention when available, but the recurrence rate may be high.[31]Panda A, Bhalla AS, Goyal A. Bronchial artery embolization in hemoptysis: a systematic review. Diagn Interv Radiol. 2017 Jul-Aug;23(4):307-17.
http://www.dirjournal.org/sayilar/90/buyuk/307-317.pdf
http://www.ncbi.nlm.nih.gov/pubmed/28703105?tool=bestpractice.com
[32]Zheng Z, Zhuang Z, Yang M, et al. Bronchial artery embolization for hemoptysis: a systematic review and meta-analysis. J Interv Med. 2021 Nov;4(4):172-80.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8947981
http://www.ncbi.nlm.nih.gov/pubmed/35586385?tool=bestpractice.com
[33]Kettenbach J, Ittrich H, Gaubert JY, et al. CIRSE standards of practice on bronchial artery embolisation. Cardiovasc Intervent Radiol. 2022 Jun;45(6):721-32.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9117352
http://www.ncbi.nlm.nih.gov/pubmed/35396612?tool=bestpractice.com
4. Surgical consideration
For patients who do not respond to embolisation or other minimally invasive techniques, surgical intervention should be considered. Some causes of haemoptysis, such as mitral stenosis, leaking aortic aneurysm, iatrogenic pulmonary artery rupture, traumatic injury to the chest, tracheo-innominate fistula, focal bronchiectasis, or aspergilloma resistant to other therapies, should be treated surgically.[5]Davidson K, Shojaee S. Managing massive hemoptysis. Chest. 2020 Jan;157(1):77-88.
http://www.ncbi.nlm.nih.gov/pubmed/31374211?tool=bestpractice.com
The thoracic surgeon should be involved early in the care of patients with massive haemoptysis, and a multi-disciplinary approach is needed to optimise the outcome.[34]Shigemura N, Wan IY, Yu SC, et al. Multidisciplinary management of life-threatening massive hemoptysis: a 10-year experience. Ann Thorac Surg. 2009 Mar;87(3):849-53.
http://www.ncbi.nlm.nih.gov/pubmed/19231404?tool=bestpractice.com
5. Other
Bridging therapies with potential to reduce bleeding severity include nebulised or bronchoscopic tranexamic acid, cold saline lavage, local epinephrine, bronchoscopic fibrinogen-thrombin injection, and tissue glue.[35]Solomonov A, Fruchter O, Zuckerman T, et al. Pulmonary hemorrhage: a novel mode of therapy. Respir Med. 2009 Feb 28;103(8):1196-200.
https://www.resmedjournal.com/article/S0954-6111(09)00056-0/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/19251406?tool=bestpractice.com
[36]Tsukamoto T, Sasaki H, Nakamura H. Treatment of hemoptysis patients by thrombin and fibrinogen-thrombin infusion therapy using a fiberoptic bronchoscope. Chest. 1989 Sep;96(3):473-6.
http://www.ncbi.nlm.nih.gov/pubmed/2670463?tool=bestpractice.com
[37]Bhattacharyya P, Dutta A, Samanta AN, et al. New procedure: bronchoscopic endobronchial sealing; a new mode of managing hemoptysis. Chest. 2002 Jun;121(6):2066-9.
http://www.ncbi.nlm.nih.gov/pubmed/12065380?tool=bestpractice.com
[38]Chawla RK, Madan A, Aditya C. Glue in hemoptysis. J Bronchology Interv Pulmonol. 2016 Oct;23(4):e40-2.
https://journals.lww.com/bronchology/fulltext/2016/10000/Glue_in_Hemoptysis.23.aspx
http://www.ncbi.nlm.nih.gov/pubmed/27764012?tool=bestpractice.com
[39]Bellam BL, Dhibar DP, Suri V, et al. Efficacy of tranexamic acid in haemoptysis: a randomized, controlled pilot study. Pulm Pharmacol Ther. 2016 Jul 25;40:80-3.
http://www.ncbi.nlm.nih.gov/pubmed/27470681?tool=bestpractice.com
[40]Prutsky G, Domecq JP, Salazar CA, et al. Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database Syst Rev. 2016 Nov 2;(11):CD008711.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008711.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/27806184?tool=bestpractice.com
[41]Wand O, Guber E, Guber A, et al. Inhaled tranexamic acid for hemoptysis treatment: a randomized controlled trial. Chest. 2018 Dec;154(6):1379-84.
https://www.doi.org/10.1016/j.chest.2018.09.026
http://www.ncbi.nlm.nih.gov/pubmed/30321510?tool=bestpractice.com
[42]Tsai YS, Hsu LW, Wu MS, et al. Effects of tranexamic acid on hemoptysis: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2020 Sep;40(9):789-797.
http://www.ncbi.nlm.nih.gov/pubmed/32661913?tool=bestpractice.com